Oxford BioMedica PLC Asset Resilience Ratio
Oxford BioMedica PLC asset resilience ratio. Oxford BioMedica PLC (OXB) has an Asset Resilience Ratio of 0.01% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OXB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oxford BioMedica PLC (2003–2022)
Asset resilience ratio of Oxford BioMedica PLC from 2003 to 2022. This chart shows how Oxford BioMedica PLC's Asset Resilience Ratio has changed over time. Read OXB total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oxford BioMedica PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OXB asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX31.00K | 0.01% |
| Total Liquid Assets | GBX31.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Oxford BioMedica PLC maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oxford BioMedica PLC Industry Peers by Asset Resilience Ratio
Compare Oxford BioMedica PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Oxford BioMedica PLC Asset Resilience Ratio by Year (2003–2022)
Oxford BioMedica PLC asset resilience ratio by year from 2003 to 2022. The table below shows the annual Asset Resilience Ratio data for Oxford BioMedica PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | GBX23.00K ≈ $2.80 |
GBX460.18 Million ≈ $55.99K |
-0.03pp |
| 2021-12-31 | 0.03% | GBX74.00K ≈ $9.00 |
GBX237.23 Million ≈ $28.86K |
-0.10pp |
| 2020-12-31 | 0.13% | GBX239.00K ≈ $29.08 |
GBX183.93 Million ≈ $22.38K |
-2.08pp |
| 2019-12-31 | 2.21% | GBX2.72 Million ≈ $330.82 |
GBX122.93 Million ≈ $14.96K |
-18.69pp |
| 2012-12-31 | 20.90% | GBX5.11 Million ≈ $621.13 |
GBX24.42 Million ≈ $2.97K |
-7.84pp |
| 2011-12-31 | 28.74% | GBX7.50 Million ≈ $912.53 |
GBX26.09 Million ≈ $3.18K |
+6.89pp |
| 2010-12-31 | 21.85% | GBX5.60 Million ≈ $681.72 |
GBX25.64 Million ≈ $3.12K |
-20.25pp |
| 2009-12-31 | 42.09% | GBX18.50 Million ≈ $2.25K |
GBX43.95 Million ≈ $5.35K |
+10.21pp |
| 2008-12-31 | 31.89% | GBX13.75 Million ≈ $1.67K |
GBX43.12 Million ≈ $5.25K |
-12.56pp |
| 2007-12-31 | 44.45% | GBX27.18 Million ≈ $3.31K |
GBX61.16 Million ≈ $7.44K |
-13.24pp |
| 2006-12-31 | 57.68% | GBX20.50 Million ≈ $2.49K |
GBX35.54 Million ≈ $4.32K |
+9.96pp |
| 2005-12-31 | 47.72% | GBX23.50 Million ≈ $2.86K |
GBX49.24 Million ≈ $5.99K |
-13.50pp |
| 2004-12-31 | 61.22% | GBX17.50 Million ≈ $2.13K |
GBX28.58 Million ≈ $3.48K |
-25.12pp |
| 2003-12-31 | 86.34% | GBX31.70 Million ≈ $3.86K |
GBX36.71 Million ≈ $4.47K |
-- |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more